Valeo Pharma Inc. announced that it has undertaken a restructuring of its commercial field operations aimed at improving margins, reducing operating expenses, aligning its commercial infrastructure with current market dynamics and accelerating its path to profitability. Valeo expects these cost reduction measures, including an approximate 20% downsizing of its workforce, will decrease its operating expenses by more than $5.0 million on an annualized basis. Combined with the previously implemented cost reduction measures announced in November 2023, total annualized costs savings from all measures will exceed $7.0 million.